This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Considerations for switching to INFLECTRA® (CT-P13*/infliximab)

A number of experts support prescriber-initiated switching, but emphasise the importance of joint decision-making between healthcare providers and patients1-4

  • Patient involvement can be vital, and no switching should occur without patient consent or knowledge1
Review local resourcePatient booklet on biosimilars

Pfizer has produced a patient friendly booklet 'What do I need to know about Biosimilar Medicines?' which may be helpful during the switching conversation

Download booklet Loading
* CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:Danese S, et al. J Crohns Colitis 2017;11:26-34. Kay J, et al. Ann Rheum Dis 2018;77:165-74. Gabi online. Spanish gastroenterologists update biosimilar position statement. 30 March 2018. Available at: Accessed May 2023. Crohn’s & Colitis Foundation. Biosimilars Position Statement. Available at: Accessed May 2023.Edwards CJ, et al. Expert Opin Biol Ther 2019;19:1001-14.Armuzzi A, et al. J Crohns Colitis 2019;13:259-66.Razanskaite V, et al. J Crohns Colitis 2017;11:690-6.
Clinical evidence

INFLECTRA® infusion therapy (CT-P13) has been evaluated across 5 randomised controlled trials

Learn more Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0166 October 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024